A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer

Launched by OSLO UNIVERSITY HOSPITAL · Apr 17, 2025

Keywords

ClinConnect Summary

The NORPACT-3 clinical trial is studying a new approach to treating patients with borderline resectable and locally advanced pancreatic cancer. This trial aims to see if giving patients chemotherapy before surgery can increase the chances of successfully removing their tumors. The goal is to have about 50% of patients with borderline resectable cancer and 15% of patients with locally advanced cancer able to undergo surgery after starting chemotherapy. The trial also aims to ensure that patients experience good overall health outcomes after their treatment.

To be eligible for this trial, participants must be at least 18 years old and have been diagnosed with a specific type of pancreatic cancer that is either borderline resectable or locally advanced. They should be fit enough to receive chemotherapy and potentially have surgery. Participants in this study can expect to receive chemotherapy first, followed by an evaluation to see if surgery is possible. The trial is being conducted in collaboration with all pancreatic surgery centers in Norway, ensuring that the treatment follows national guidelines for safety and effectiveness.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Borderline resectable or locally advanced adenocarcinoma of the pancreas (NCCN, version 2, 2021) (Appendix 3)
• • Nx, M0 (UICC 8th version, 2016)
• • Cytological or histological confirmation of adenocarcinoma
• • Age \>18 year
• • Considered able to receive primary chemotherapy and possible surgery
• • Written informed consent
• Exclusion Criteria:
• • Co-morbidity or performance status precluding primary chemotherapy
• • Co-morbidity or performance status precluding pancreatectomy
• • Female patients in child-bearing age not using adequate contraception, pregnant or lactating women
• • Mental or physical disorders that could interfere with treatment of with the provision of informed consent
• • Any reason why, in the opinion of the investigator, the patient should not participate